Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

NCT03897127 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT03897127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03897127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
Lead sponsor
University of Ulm
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 4, 2019
Completion date
June 30, 2027
Enrollment
882 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia